Article: Renagel in New Dialysis Study Published in Kidney International.

Data Show That Patients Treated with Renagel Achieve Mortality Benefit

CAMBRIDGE, Mass., Jan. 8 /PRNewswire-FirstCall/ -- Genzyme Corporation announced today that findings published in the online version of Kidney International demonstrate that patients using Renagel experienced a significantly lower rate of death compared with patients using calcium-based phosphate binders in a newly completed study.

The results were drawn from the Renagel in New Dialysis study (RIND), a randomized open-label trial involving 127 patients new to hemodialysis at five dialysis centers in the United States. All-cause mortality was a pre-specified secondary endpoint. ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!